Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA
Biotech
Krystal discontinues melanoma study after FDA's Replimune rebuff
The FDA’s rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting Krystal Biotech to shutter a clinical trial.
Gabrielle Masson
Aug 21, 2025 10:50am
FDA aims for September approval decision for Stealth's drug
Aug 21, 2025 10:15am
After 'complete standstill,' biotech market reaches new normal
Aug 20, 2025 11:04am
FDA clears Signos' over-the-counter, CGM-powered weight loss app
Aug 20, 2025 10:44am
Rocket's gene therapy free from FDA hold
Aug 20, 2025 10:40am
FDA snubs PTC's Friedreich's ataxia hopeful with CRL
Aug 19, 2025 10:55am
